TrialsgrambetaRCTs are beautiful

Glomerular & immune kidney disease

IgA nephropathy, membranous nephropathy, lupus nephritis, ANCA vasculitis and FSGS.

Trials
12
Years
1984–2025
Sort
  • 2025APPLAUSE-IgAN⁠IgA nephropathyIn 250 patients with IgA nephropathy and persistent proteinuria, the factor-B inhibitor iptacopan reduced proteinuria compared with placebo.Read →
  • 2023NefIgArd⁠IgA nephropathyIn 364 patients with IgA nephropathy on optimised RAS blockade, targeted-release budesonide preserved eGFR and reduced proteinuria compared with placebo.Read →
  • 2023PROTECT 2023⁠IgA nephropathyIn 404 patients with IgA nephropathy and proteinuria despite maximal RAS blockade, sparsentan reduced proteinuria compared with irbesartan.-49.8% vs -15.1%Read →
  • 2023DUPLEX⁠FSGSIn 371 patients with focal segmental glomerulosclerosis, sparsentan reduced proteinuria but did not significantly improve eGFR slope compared with irbesartan.Read →
  • 2021AURORA 1⁠Lupus nephritisIn 357 patients with active lupus nephritis, adding voclosporin to MMF and low-dose steroids increased complete renal response at week 52 compared with placebo.OR 2.6595% CI 1.64-4.27Read →
  • 2021ADVOCATE⁠ANCA vasculitisIn 331 patients with ANCA-associated vasculitis, the oral C5a-receptor antagonist avacopan improved sustained remission at week 52 compared with a tapering prednisone regimen.65.7% vs 54.9%Read →
  • 2020BLISS-LN⁠Lupus nephritisIn 448 patients with active lupus nephritis, adding belimumab to standard therapy increased renal response at week 104 compared with placebo.OR 1.55CI 1.04-2.32Read →
  • 2020PEXIVAS Core⁠ANCA vasculitisIn 704 patients with severe ANCA-associated vasculitis, plasma exchange did not reduce death or end-stage kidney disease compared with no plasma exchange.HR 0.8695% CI 0.65-1.13Read →
  • 2019MENTOR⁠Membranous nephropathyIn 130 patients with membranous nephropathy at moderate-to-high risk, rituximab achieved more complete or partial remission at 24 months than cyclosporine.60% vs 20%Read →
  • 2010RAVE Core⁠ANCA vasculitisIn 197 patients with severe ANCA-associated vasculitis, rituximab was non-inferior for inducing remission compared with cyclophosphamide.64% vs 53%Read →
  • 2009ALMS⁠Lupus nephritisIn 370 patients with active lupus nephritis, mycophenolate mofetil was non-inferior for induction response and superior for maintenance versus cyclophosphamide then azathioprine.Read →
  • 1984Ponticelli⁠Membranous nephropathyIn 62 patients with idiopathic membranous nephropathy, alternating monthly methylprednisolone and a cytotoxic agent increased remission of nephrotic syndrome compared with supportive care.72% vs 30%Read →